MarginsXMarginsX
Home › Markets › Health Care › SRRK

Scholar Rock Holding Corporation (SRRK)

SRRK trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$44.54
+3.09% on the day
Market cap
$5.4B
Mid cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$377.9M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1727196/000110465926022551/0001104659-26-022551-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSRRK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001727196
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$377.9M
Operating income-$384.6M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$323.5M
Total assets$404.3M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
14.2 months
$366.3M cash at September 30, 2026
Share count, 1 year
+19.6%
2025-11-05 to 2026-11-06 · +69.1% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$599K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$366.3M cash; operating cash flow -$77.4M a quarter.Report 2026-09-30
Shares outstanding122,004,478 (2026-11-06); 102,007,457 a year earlier; 72,143,258 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Boston, Massachusetts, United States; changed auditors 2 times in 24 months8-K 4.01 2025-06-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20.0M, sold $19.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$570K-$107.2M-$81.8M$366.3M$196.2M$570K10-Q 2026-11-10
Q2 2026
2026-06-30
$0-$109.9M-$70.3M$437.1M$196.2M$010-Q 2026-08-06
Q1 2026
2026-03-31
$0-$105.5M-$82.1M$430.5M$196.6MNeeds four quarters10-Q 2026-05-07
Q4 2025
2025-12-31
$0-$91.0M-$75.5M$323.5M$99.7M$010-K 2026-03-03
Q3 2025
2025-09-30
$0-$102.2M-$68.9M$286.8M$99.6MNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$110.0M-$76.9M$152.9M$49.8MNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$74.7M-$78.7M$137.9M$49.7MNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$66.5M-$49.5M$177.9M$50.1MNeeds four quarters10-K 2026-03-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-03-03
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 653 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-8.0%
1 month+6.6%
3 months-18.6%
Year to date-1.9%
1 year+43.7%
From 52-week high-28.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IBRXImmunityBio Inc.$5.98-0.66%$6.4B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
KODKodiak Sciences Inc$100.73-9.41%$6.6B
IMVTImmunovant Inc.$33.28-2.63%$6.9B
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
TARSTarsus Pharmaceuticals Inc.$78.68-1.99%$3.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier